107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China
B. Liu, J. Yao, H. Zhong, J. Li, S. Zhang, Y. Sun, H. Ge, Q. Shi 等 17 位
Harbin Medical University Third Affiliated Hospital of Harbin Medical University First Affiliated Hospital of Henan University of Science and Technology Shanghai Chest Hospital
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
In HARMONi-2 study, ivonescimab significantly improved progression free survival (PFS) compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer (NSCLC), with manageable safety profile. Here we reported health-related quality of life (HRQoL) from HARMONi-2.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同，数值存在差异属正常。
AI 辅助阅读
依据：摘要
可就本文提问；依据不足时会说明。
学术脉络
学科主题
生物医学Cancer Immunotherapy and Biomarkers
Lung Cancer Treatments and Mutations · Lung Cancer Diagnosis and Treatment